|
WO2021072286A1
|
|
Cancer combination treatments using anti-stat3 nucleic acid conjugates
|
|
WO2021067513A1
|
|
Metal chelating agents and methods of using the same
|
|
WO2021051009A1
|
|
Methods and compositions to direct breakdown of insulin mrna in benign fashion
|
|
WO2021041336A1
|
|
Igg antibody compositions and methods of making the same
|
|
US2021077535A1
|
|
Neural stem cell delivery of therapeutic agents
|
|
WO2021035045A1
|
|
Mettl16 inhibitors and uses thereof
|
|
WO2021030586A1
|
|
Dual bispecific antibody compounds and uses thereof
|
|
WO2021030484A2
|
|
Il1rap antibodies
|
|
US2021115113A1
|
|
Epstein-barr virus antibodies and uses thereof
|
|
US2021023238A1
|
|
Triptolide antibody conjugates
|
|
WO2021016464A1
|
|
Methods and compositions for treating cancer
|
|
WO2020264043A1
|
|
Pdl1 positive nk cell cancer treatment
|
|
US2020399643A1
|
|
P38 map kinase inhibitors
|
|
WO2020243713A2
|
|
Cd33 targeted chimeric antigen receptor modified t cells for treatment of cd33 positive malignancies
|
|
US2020378954A1
|
|
Detecting cytokine signaling responsiveness in immune cells
|
|
US2020375558A1
|
|
Multi-modal image-guided radiation system
|
|
WO2020243007A1
|
|
Ccr4 targeted chimeric antigen receptor modified t cells for treatment of ccr4 positive malignancies
|
|
WO2020232389A1
|
|
Compositions and methods for targeting tumor-associated extracellular matrix components to improve drug delivery
|
|
WO2020205751A1
|
|
Methods for manufacturing t cells expressing of chimeric antigen receptors and other receptors
|
|
WO2020190984A1
|
|
Compounds for the treatment of neuropathic pain
|
